Natural-derived polyphenols as potential anticancer agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 8, 2012, Pages 902-918

  Spatafora, Carmela ^a   Tringali, Corrado ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Anticancer agents; Flavonoids; Polyphenols; Stilbenoids; Structure activity relationship

Indexed keywords

ANTINEOPLASTIC AGENT; CAFFEIC ACID DERIVATIVE; CHALCONE; COMBRETASTATIN A4; FLAVONOID; FLAVOPIRIDOL; GENISTEIN; MITOXANTRONE; PACLITAXEL; POLYPHENOL DERIVATIVE; RESVERATROL; TUBULIN;

ANTIANGIOGENIC ACTIVITY; ATYPICAL CHRONIC MYELOID LEUKEMIA; BIOAVAILABILITY; BLOOD BRAIN BARRIER; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RISK; COLON CANCER; DRUG CYTOTOXICITY; GLIOBLASTOMA; HEPATOMA CELL; HUMAN; IN VIVO STUDY; LUNG SMALL CELL CANCER; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL PRODUCTS; HUMANS; NEOPLASMS; POLYPHENOLS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866433129     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802649996     Document Type: Review

References (94)

1. Pezzuto, J.M. Resveratrol as an Inhibitor of Carcinogenesis. Pharm. Biol., 2008, 46, 443-573.
2. Renaud, S.C.; De Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet, 1992, 339, 1523-1526.
3. Spatafora, C.; Tringali, C. From Natural Polyphenols to Synthetic Antitumor Agents In: Bioactive Compounds from Natural Sources, Second Edition: Natural Products as Lead Compounds in Drug Discovery, C. Tringali Ed., 299-338, CRC Press/Taylor & Francis, Boca Raton, 2012.
4. Loa, J.; Chow P.; Zhang, K. Studies of structure-activity relationship on plant polyphenol-induced suppression of human liver cancer cells. Cancer Chemother. Pharmacol., 2009, 63, 1007-1016.
5. Kumar, S.K.; Hager, E.; Pettit, C.; Gurulingappa, H.; Davidson, N.E.; Khan. S.R. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J. Med. Chem., 2003, 46, 2813-2815.
6. Go, M.L.; Wu, X.; Liu, X.L. Chalcones An update on cytotoxic and chemopreventive properties. Curr. Med. Chem., 2005, 12, 483-499.
7. Achanta, G.; Modzelewska, A.; Feng, L.; Khan, S. R.; Huang, P. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Molec. Pharmacol., 2006, 70, 426-433.
8. Modzelewska, A.; Pettit, C.; Achanta, G.; Davidson, N.E.; Huang, P.; Khan S.R. Anticancer activities of novel chalcone and bischalcone derivatives. Bioorg. Med. Chem., 2006, 14, 3491-3495.
9. Katsori, A.M.; Hadjipavlou-Litina D. Chalcones in cancer: understanding their role in terms of QSAR. Curr. Med. Chem., 2009, 16, 1062-1081.
10. Srinivas, K.V.; Koteswara, R.Y.; Mahender, I.; Das, B.; Rama Krishna, K.V.S.; Hara, Kishore K.; Murty, U.S.N. Flavonoids from Caesalpinia pulcherrima. Phytochemistry, 2003, 63, 789-793.
11. Boumendjel, A.; Boccard, J.; Carrupt, P.-A.; Nicolle, E.; Blanc, M.; Geze, A.; Choisnard, L.; Wouessidjewe, D.; Matera, E.-L.; Dumontet C. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. J. Med. Chem., 2008, 51, 2307-2310.
12. Boumendjel A., McLeer-Florin, A.; Champelovier, P.; Allegro, D.; Muhammad, D.; Souard, F.; Derouazi, M.; Peyrot, V.; Toussaintand B.; Boutonnat, J. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC Cancer, 2009, 9, 242.
13. Bandgar, B.P., Gawande, S.S., Bodade, R.G., Totre, J.V., Khobragade C.N., Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents. Bioorg. Med. Chem., 2010, 18, 1364-1370.
14. Dyrager, C.; Wickström, M.; Fridén-Saxin, M.; Friberg, A.; Dahlén, K.; Wallén, E.A.A.; Gullbo, J.; Grøtli, M.; Luthman, K. Inhibitors and promoters of tubulin polymerization: Synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents. Bioorg. Med. Chem., 2011, 19, 2659-2665.
15. Edwards, M.L.; Stemerick, D.M.; Sunkara, P.S. Chalcones: A new class of antimitotic agents J. Med. Chem., 1990, 33, 1948-1954.
16. Ducki, S. Antimitotic chalcones and related compounds as inhibitors of tubulin assembly Anti-Cancer Agents Med. Chem., 2009, 9, 336-347.
17. Peyrot, V.; Leynadier, D.; Sarrazin, M.; Briand, C.; Rodriquez, A.; Nieto, J.M.; Andreu, J.M. Interaction of tubulin and cellular microtubules with the new antitumor drug MDL 27048. A powerful and reversible microtubule inhibitor. J. Biol. Chem., 1989, 264, 21296-21301.
18. Peyrot, V.; Leynadier, D.; Sarrazin, M.; Briand, C.; Menendez, M.; Laynez, J.; Andreu, J.M. Mechanism of binding of the new antimitotic drug MDL 27048 to the colchicine site of tubulin: Equilibrium studies. Biochemistry, 1992, 31, 11125-11132.
19. Ducki, S.; Rennison, D.; Woo, M.; Kendall, A.; Fournier Dit Chabert, J.; McGown, A.T.; Lawrence, N.J. Combretastatin -like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity. Bioorg. Med. Chem., 2009, 17, 7698-7710.
20. Ducki, S.; MacKenzie, G.; Greedy, B.; Armitage, S.; Fournier Dit Chabert, J.; Bennett, E.; Nettles, J.; Snyder, J.P.; Lawrence N.J. Combretastatin - like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg. Med. Chem., 2009, 17, 7711-7722.
21. Kong, Y.; Wang, K.; Edler, M.C.; Hamel, E.; Mooberry, S.L.; Paigeand M. A.; Brown, M.L. A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg. Med. Chem., 2010, 18, 971-977.
22. Nakagawa-Goto, K.; Chen, T.-H.; Peng, C.-Y.; Bastow, K.F.; Wu, J.-H.; Lee, K.-H. Antitumor Agents 259. Design, Syntheses, and Structure-Activity Relationship Study of Desmosdumotin C Analogs. J. Med. Chem., 2007, 50, 3354-3358.
23. Wu, J.H.; McPhail, A.T.; Bastow, K.F.; Shiraki, H.; Ito, J.; Lee. K. H. Desmosdumotin C, a new cytotoxic principle from Desmos dumosus. Tetrahedron Lett., 2002, 43, 1391-1393.
24. Nakagawa-Goto, K.; Wua, P.-C.; Bastow, K.F.; Yang, S.-C.; Yu, S.-L.; Chen, H.-Y.; Lin, J.-C.; Goto, M.; Morris-Natschke, S.L.; Yang, P.-C.; Lee, K.-H. Antitumor agents 283. Further elaboration of Desmosdumotin C analogs as potent antitumor agents: Activation of spindle assembly checkpoint as possible mode of action. Bioorg. Med. Chem., 2011, 19, 1816-1822.
25. Yoon, G.; Kang, B.Y.; Cheon, S.H. Topoisomerase I inhibition and cytotoxicity of licochalcone A and E from Glycyrrhiza inflata. Arch. Pharm. Res., 2007, 30, 313-316.
26. Na, Y.; Nam, J.-M. Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy-and thiiranylmethoxy-chalcone derivatives. Bioorg. Med. Chem. Lett., 2011, 21, 211-214.
27. Chen, L.; Zhang, H.-Y. Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate. Molecules, 2007, 12, 946-957.
28. Nagle, D.G.; Ferreira, D.; Zhou, Y.-D. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry, 2006, 67, 1849-1855.
29. Lambert, J.D.; Sang, S.; Hong, J.; Kwon, S.-J.; Lee, M.-J.; Ho, C.-T.; Yang, C.S. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. Drug Metab. Dispos., 2006, 34, 2111-2116.
30. Sánchez-del-Campo, L.; Otón, F.; Tárraga, A.; Cabezas-Herrera, J.; Chazarra, S.; Rodríguez-López, J.N. Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate. J. Med. Chem., 2008, 51, 2018-2026.
31. Sanchez-del-Campo, L.; Tarraga, A.; Montenegro, M. F.; Cabezas-Herrera, J.; Rodriguez-Lopez, J.N. Melanoma activation of 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase. Mol. Pharm., 2009, 6, 883-894.
32. Lamy, S.; Gingras, D.; Béliveau, R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res., 2002, 62, 381-385.
33. Matsubara, K.; Saito, A.; Tanaka, A.; Nakajima, N.; Akagi, R.; Mori, M.; Mizushina, Y. Epicatechin conjugated with fatty acid is a potent inhibitor of DNA polymerase and angiogenesis. Life Sci., 2007, 80, 1578-1585.
34. Tanaka, H.; Yamanouchi, M.; Miyoshi, H.; Hirotsu, K.; Tachibana, H.; Takahashi, T. Solid-Phase synthesis of a combinatorial methylated (±)-epigallocatechin gallate library and the growth-inhibitory effects of these compounds on melanoma b16 cells. Chem. -Asian J., 2010, 5, 2231-2248.
35. Cardenas, M.; Marder, M.; Blank, V.C.; Roguin, L.P.; Leonor, P. Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines. Bioorg. Med. Chem., 2006, 14, 2966-2971.
36. Lv, P.-C.; Wang, K.-R.; Li, Q.-S.; Chen, J.; Sun, J.; Zhu, H.-L. Design, synthesis and biological evaluation of chrysin long-chain derivatives as potential anticancer agents. Bioorg. Med. Chem., 2010, 18, 1117-1123.
37. Walle, T. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? Semin. Cancer Biol., 2007, 17, 354-362.
38. Lewin, G.; Maciuk, A.; Thoret, S.; Aubert, G.; Dubois, J.; Cresteil, T. Semisynthesis of natural flavones inhibiting tubulin polymerization, from hesperidin. J. Nat. Prod., 2010, 73, 702-706.
39. Lewin, G.; Shridhar, N.B.; Aubert, G.; Thoret, S.; Dubois, J.; Cresteil, T. Synthesis of antiproliferative flavones from calycopterin, major flavonoid of Calycopteris floribunda Lamk. Bioorg. Med. Chem., 2011, 19, 186-196.
40. Yenjai, C.; Wanich, S. Cytotoxicity against KB and NCI-H187 cell lines of modified flavonoids from Kaempferia parviflora. Bioorg. Med. Chem. Lett., 2010, 20, 2821-2823.
41. Ferlin, M.G.; Conconi, M.T.; Urbani, L.; Oselladore, B.; Guidolin, D.; Di Liddo, R.; Parnigotto, P.P. Synthesis, in vitro and in vivo preliminary evaluation of anti-angiogenic properties of some pyrroloazaflavones. Bioorg. Med. Chem., 2011, 19, 448-457.
42. Bobrowska-Hagerstrand, M.; Wrobel, A.; Mrowczynska, L.; Soderstrom, T.; Shirataki, Y.; Motohashi, N.; Molnar, J.; Michalak, K.; Hagerstrand, H. Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure-activity relationship study. Oncol. Res., 2003, 13, 463-469.
43. Poerwono, H.; Sasaki, S.; Hattori, Y.; Higashiyama, K. Efficient microwave-assisted prenylation of pinostrobin and biological evaluation of its derivatives as antitumor agents. Bioorg. Med. Chem. Lett., 2010, 20, 2086-2089.
44. Kim, Y.W.; Hackett, J.C.; Brueggemeier, R.W. Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J. Med. Chem., 2004, 47, 4032-4040.
45. Li, H.-Q., Ge, H.-M.; Chen, Y.-X.; Xu, C.; Shi, L.; Ding, H.; Zhu, H.-L.; Tan R.-X. Synthesis and cytotoxic evaluation of a series of genistein derivatives. Chem. Biodiv., 2006, 3,463-472.
46. Rusin, A.; Zawisza-Puchałka, J.; Kujawa, K.; Gogler-Pigłowska, A.; Wietrzyk, J.; Switalska, M.; Głowala-Kosinska, M.; Gruca, A.; Szeja, W.; Krawczyk, Z.; Grynkiewicz, G. Synthetic conjugates of genistein affecting proliferation and mitosis of cancer cells. Bioorg. Med. Chem., 2011, 19, 295-305.
47. Hadden, M.K.; Galam, L.; Matts, R.L.; Blagg, B.S.J. Derrubone, an inhibitor of the Hsp90 protein folding machinery J. Nat. Prod., 2007, 70, 2014-2018.
48. Hastings, J.M.; Hadden, M.K.; Blagg, B.S.J. Synthesis and Evaluation of Derrubone and Select Analogues J. Org. Chem. 2008, 73, 369-373.
49. Yokosuka, A.; Haraguchi, M.; Usui, T.; Kazami, S.; Osada, H.; Yamori, T.; Mimaki, Y. Glaziovianin A, a new isoflavone, from the leaves of Ateleia glazioviana and its cytotoxic activity against human cancer cells. Bioorg. Med. Chem. Lett. 2007, 17, 3091-3094.
50. Hayakawa, I.; Ikedo, A.; Kigoshi, H. Synthesis of glaziovianin A: a potent antitumor isoflavone. Chem. Lett., 2007, 36, 1382-1383.
51. Ikedo, A.; Hayakawa, I.; Usui, T.; Kazami, S.; Osada, H.; Kigoshi, H. Structure-activity relationship study of glaziovianin A against cell cycle progression and spindle formation of HeLa S3 cells. Bioorg. Med. Chem. Lett., 2010, 20, 5402-5404.
52. Katalinic, V.; Mozina, S.S.; Skroza, D.; Generalic, I.; Abramovic, H.; Milos, M.; Ljubenkov, I.; Piskernik, S.; Pezo, I.; Terpinc, P.; Boban, M. Polyphenolic profile, antioxidant properties and antimicrobial activity of grape skin extracts of 14 Vitis vinifera varieties grown in Dalmatia (Croatia). Food Chem., 2009, 119, 715-723.
53. Vang, O.; Ahmad, N.; Baile, C.A.; Baur, J.A.; Brown, K.; Csiszar, A.; Das, D.K.; Delmas, D.; Gottfried, C.; Lin, H.-Y.; Ma, Q.-Y.; Mukhopadhyay, P.; Nalini, N.; Pezzuto, J.M.; Richard, T.; Shukla, Y.; Surh, Y.-J.; Szekeres, T.; Szkudelski, T.; Walle, T.; Wu, J.M.; What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol. PLoS ONE 2011, 6, e19881.
54. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506.
55. Walle, T. Bioavailability of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 9-15.
56. Chillemi, R.; Sciuto, S.; Spatafora, C.; Tringali, C. Anti-tumor properties of stilbene-based resveratrol analogues: recent results Nat. Prod. Comm., 2007, 2, 499-513.
57. Nicolosi, G.; Spatafora, C.; Tringali, C. Chemo-enzymatic preparation of resveratrol derivatives. J. Mol. Cat. B: Enz., 2002, 16, 223-229.
58. Cardile, V.; Lombardo, L.; Spatafora, C.; Tringali, C. Chemoenzymatic synthesis and antiproliferative activity of resveratrol analogues. Bioorg. Chem., 2005, 33, 22-33.
59. MacRae, W.D.; Towers, G.H.N. Non-alkaloidal constituents of Virola elongate bark. Phytochemistry, 1985, 24, 561-566.
60. Belleri, M.; Ribatti, D.; Nicoli, S.; Cotelli, F.; Forti, L.; Vannini, V.; Stivala L.A.; Presta, M. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4′-trimethoxystilbene. Mol. Pharmacol. 2005, 67, 1451-1459.
61. Hsieh, T.-C.; Huang, Y.-C.; Wu, J.M. Control of prostate cell growth, DNA damage and repair and gene expression by resveratrol analogues, in vitro. Carcinogenesis, 2011, 32, 93-101.
62. Cardile, V., Chillemi, R.; Lombardo, L.; Sciuto, S.; Spatafora C.; Tringali C. Antiproliferative activity of methylated analogues of E-and Z-resveratrol. Z. Naturforsch. 62 c, 2007, 189-195.
63. Schneider, Y.; Chabert, P.; Stutzmann, J.; Coelho, D.; Fougerousse, A.; Gosse, F.; Launay, J.-F.; Brouillard, R.; Raul, F. Resveratrol analog (Z)-3,5,4′-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int. J. Cancer, 2003, 107, 189-196.
64. Simoni D., Roberti, M.; Invidiata, F.P.; Aiello, E.; Aiello, S.; Marchetti, P.; Baruchello, R.; Eleopra, M.; Di Cristina, A.; Grimaudo, S.; Gebbia, N.; Crosta, L.; Dieli F.; Tolomeo, M. Stilbene-based anticancer agents: Resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism. Bioorg. Med. Chem. Lett., 2006, 16, 3245-3248.
65. Zhang, W.; Go, M.L. Methoxylation of resveratrol: Effects on induction of NAD(P)H Quinone-oxidoreductase 1 (NQO1) activity and growth inhibitory properties. Bioorg. Med. Chem. Lett., 2011, 21, 1032-1035.
66. Cuendet, M.; Oteham, C.P.; Moon, R.C.; Pezzuto, J.M. Quinone reductase induction as a biomarker for cancer chemoprevention. J. Nat. Prod., 2006, 69, 460-463.
67. Tron, G.C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A.A. Medicinal chemistry of combretastatin A4: Present and future directions. J. Med. Chem., 2006, 49, 3033-3044.
68. Kingston D.G.I. Tubulin-interactive natural products as anticancer agents. J. Nat. Prod., 2009, 72, 507-515.
69. Cai, Y.-C.; Zou, Y.; Ye Y.-L.; Sun, H.-Y.; Su, Q.-G.; Wang, Z.-X.; Zeng Z.-L.; Xian, L.-J. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4′,5-trimethoxylstilbene-3′-O-phosphate disodium (M410). Invest. New Drugs 2011, 29, 300-311.
70. Mazué, F.; Colin, D.; Gobbo, J.; Wegner, M.; Rescifina, A.; Spatafora, C.; Fasseur, D.; Delmas, D.; Meunier, P.; Tringali, C.; Latruffe, N. Structural determinants of resveratrol for cell proliferation inhibition potency: experimental and docking studies of new analogs. Eur. J. Med. Chem., 2010, 45, 2972-2980.
71. Cao, T. M.; Durrant, D.; Tripathi, A.; Liu, J.; Tsai, S.; Kellogg, G.E.; Simoni, D.; Lee, R.M. Stilbene derivatives that are colchicine site microtubule inhibitors have antileukemic activity and minimal systemic toxicity. Am. J. Hematol., 2008, 83, 390-397.
72. Androutsopoulos, V.P.; Ruparelia, K.C.; Papakyriakou, A.; Filippakis, H.; Tsatsakis, A.M.; Spandidos, D.A. Anticancer effects of the metabolic products of the resveratrol analogue, DMU-212: Structural requirements for potency. Eur. J. Med. Chem., 2011, 46, 2586-2595.
73. Sale, S.; Verschoyle, R.D.; Boocock, D.; Jones, D.J.; Wilsher, N., Ruparelia, K.C., Potter, G.A.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans-3,4,5,4′-tetramethoxystilbene. Br. J. Cancer, 2004, 90, 736-744.
74. Huang, X.-F.; Ruan, B.-F.; Wang, X.-T.; Xu, C.; Ge, H.-M.; Zhu, H.-L.; Tan, V. Synthesis and cytotoxic evaluation of a series of resveratrol derivatives modified in C2 position. Eur. J. Med. Chem., 2007, 42, 263-267.
75. Spatafora, C.; Basini, G.; Baioni, L.; Grasselli, F.; Sofia, A.; Tringali, C. Antiangiogenic resveratrol analogues by mild m-CPBA aromatic hydroxylation of 3,5-dimethoxystilbenes. Nat. Prod. Comm., 2009, 4, 239-246.
76. Basini, G.; Tringali, C.; Baioni, L.; Bussolati, S.; Spatafora, C.; Grasselli, F. Biological effects on granulosa cells of hydroxylated and methylated resveratrol analogues. Mol. Nutr. Food Res., 2010, 54, S236-243.
77. Chae, Y.S.; Kim, J.G.; Jung, H.J.; Yang, J.D.; Jung, J.H.; Aiyar, S.E.; Kim, S.; Park, H. Anticancer effect of (E)-2-hydroxy-3′,4,5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization. Cancer Chemother. Pharmacol., 2011, 68, 349-358.
78. Ma, Z.; Molavi, O.; Haddadi, A.; Lai, R.; Gossage, R.A.; Lavasanifar, A. Resveratrol analog trans 3, 4, 5, 4'-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother. Pharmacol., 2008, 63, 27-35.
79. Park, H.; Aiyar, S.E.; Fan, P.; Wang, J.; Yue, W.; Okouneva, T.; Cox, C.; Jordan, M.A.; Demers, L.; Cho, H.; Kim, S.; Song, R.X.; Santen, R.J. Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. Cancer Res., 2007, 67, 5717-5726.
80. Chun, Y.-J.; Lim, C.; Ohk, S.O.; Lee, J.M.; Lee, J.H.; Choi, S.; Kim S. trans-Stilbenoids: potent and selective inhibitors for human cytochrome P450 1B1. Med. Chem. Commun., 2011, 2, 402-405.
81. Chun, Y.-J.; Kim, S.; Kim, D.; Lee, S.-K.; Guengerich. F.P. A new selective and potent inhibitor of human Cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res., 2001, 61, 8164-8170.
82. Lin, H. S. and P. C. Ho. A rapid HPLC method for the quantification of 3,5,4′-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. J. Pharm. Biomed. Anal., 2009, 49: 387-392.
83. Saiko, P; Pemberger, M.; Horvath, Z.; Savinc, I.; Grusch, M.; Handler, N.; Erker, T.; Jaeger, W.; Fritzer-Szekeres, M.; Szekeres, T. Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity. Oncol. Rep. 2008, 19, 1621-1626.
84. Ferreira, M.-J.U.; Duarte, N.; Gyémánt, N.; Radics, R.; Cherepnev, G.; Varga, A.; Molnar, J. Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells. Anticancer Res., 2006, 26, 3541-3546.
85. Valdameri, G.; Pereira, L.R.; Spatafora, C.; Guitton, J.; Gauthier, C.; Arnaud, O.; Pereira Ferreira, A.; Falson, P.; Winnischofer, S.M.B.; Rocha, M.E.M.; Tringali, C.; Di Pietro, A. Methoxy stilbenes as potent, specific, untransported and not-cytotoxic inhibitors of breast cancer resistance protein. ACS Chemical Biology 2012, 7, 322-330.
86. Lin, H.-S.; Tringali, C.; Spatafora, C.; Choo, Q.-Y., Ho, P.C. LC determination of trans-3,5,3′,4′,5′-pentamethoxystilbene in rat plasma. Chromatographia, 2010, 72, 827-832.
87. Weng C. J.; Yang, Y.T.; Ho, C.T.; Yen, G.C. Mechanisms of apoptotic effects induced by resveratrol, dibenzoylmethane, and their analogues on human lung carcinoma cells. J. Agric. Food. Chem., 2009, 57, 5235-5243.
88. Pan, M.-H.; Lin, C.-L.; Tsai, J.-H.; Ho, C.-T.; Chen, W.-J. 3,5,3′,4′,5′-Pentamethoxystilbene (MR-5), a synthetically methoxylated analogue of resveratrol, inhibits growth and induces G1 cell cycle arrest of human breast carcinoma MCF-7 cells. J. Agric. Food Chem., 2010, 58, 226-234.
89. Li, H.; Wu, W.K.K.; Zheng, Z.; Che, C.T.; Yu, L.; Li, Z.J.; Wu, Y.C.; Cheng, K.-W.; Yu, J.; Cho, C.H.; Wang, M. 2,3′,4,4′,5′-Pentamethoxy-trans-stilbene, a resveratrol derivative, is a potent inducer of apoptosis in colon cancer cells via targeting microtubules. Biochem. Pharm., 2009, 78, 1224-1232.
90. Li, H.; Wu, W.K.K.; Li, Z.J.; Chan, K.M.; Wong, C.C.M.; Ye, C.G.; Yu, L.; Sung, J.J.Y.; Cho, C.H.; Wang, M. 2,3′,4,4′,5′-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice. Brit. J. Pharm., 2010, 160, 1352-1361.
91. Moran, B.W.; Anderson, F.P.; Devery, A.; Cloonan, S.; Butler, W.E.; Varughese, S.; Draper, S.M.; Kenny, P.T.M. Synthesis, structural characterisation and biological evaluation of fluorinated analogues of resveratrol. Bioorg. Med. Chem., 2009, 17, 4510-4522.
92. Zhang, W.; Sviripa, V.; Kril, L.M.; Chen, X.; Yu, T.; Shi, J.; Rychahou, P.; Evers, B.M.; Watt, D.S.; Liu, C. Fluorinated N,N-Dialkylaminostilbenes for Wnt Pathway Inhibition and Colon Cancer Repression. J. Med. Chem., 2011, 54, 1288-1297.
93. Cheng, L.-X.; Tang, J.-J.; Luo, H.; Jin, X.-L.; Dai, F.; Yang, J.; Qian, Y.-P.; Li, X.-Z.; Zhou, B. Antioxidant and antiproliferative activities of hydroxyl-substituted Schiff bases. Bioorg. Med. Chem. Lett., 2010, 20, 2417-2420.
94. Ruan, B.-F.; Lu, X.; Tang, J.-F.; Wei, Y.; Wang, X.-L.; Zhang, Y.-B.; Wang, L.-S.; Zhu, H.-L.; Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents. Bioorg. Med. Chem., 2011, 19, 2688-2695.